公开(公告)号：US20240156949A1

公开(公告)日：2024-05-16

申请号：US18494893

申请日：2023-10-26

Applicant: GlaxoSmithKline Biologicals SA ,  CureVac SE

Inventor： Benjamin PETSCH ,  Dominik VAHRENHORST ,  Diego CHAVES MORENO ,  Janina GERGEN ,  Jessica Michelle DEVANT ,  Kristina KOVACIKOVA ,  Hans Wolfgang GROßE

IPC: A61K39/215 ,  A61P31/14 ,  C07K14/005

CPC classification number: A61K39/215 ,  A61P31/14 ,  C07K14/005 ,  A61K2039/53 ,  C12N2770/20022 ,  C12N2770/20034

Abstract: The present invention is directed to nucleic acids suitable for use in treatment or prophylaxis of an infection with a coronavirus, such as a Coronavirus SARS-CoV-2 variant, or a disorder related to such an infection, such as COVID-19. The present invention is also directed to compositions, and vaccines. The compositions and vaccines comprise at least one of said nucleic acid sequences, and nucleic acid sequences in association with a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acids, the composition, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, such as a Coronavirus infection from a SARS-CoV-2 variant.

公开(公告)号：US20240156946A1

公开(公告)日：2024-05-16

申请号：US18268736

申请日：2021-12-21

Applicant: CUREVAC SE ,  GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Nicole ROTH ,  Diego Chaves MORENO ,  Hans Wolfgang GROßE ,  Dominik VAHRENHORST ,  Susanne RAUCH

IPC: A61K39/215 ,  C07K14/005

CPC classification number: A61K39/215 ,  C07K14/005 ,  A61K2039/6018

Abstract: The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

公开(公告)号：US20240150386A1

公开(公告)日：2024-05-09

申请号：US18320598

申请日：2023-05-19

Applicant: CureVac SE

Inventor： Stefan HEINZ ,  Tilmann ROOS ,  Dominik VAHRENHORST ,  Markus CONZELMANN

IPC: C07H1/06 ,  A61K31/713

CPC classification number: C07H1/06 ,  A61K31/713

Abstract: The present invention is directed to a method for modifying the retention time of RNA on a chromatographic column. The present invention also concerns a method for purifying RNA from a mixture of at least two RNA species. Furthermore, the present invention relates to a method for co-purifying at least two RNA species from a mixture of at least two RNA species. In particular, the present invention provides a method for harmonizing the numbers of A and/or U nucleotides in at least two RNA species. The present invention is also directed to RNA obtainable by said methods, a composition comprising said RNA or a vaccine comprising said RNA and methods for producing such RNA and compositions. Further, the invention concerns a kit, particularly a kit of parts, comprising the RNA, composition or vaccine. The invention is further directed to a method of treating or preventing a disorder or a disease, first and second medical uses of the RNA, composition and vaccine. Moreover, the present invention concerns a method for providing an adapted RNA sequence or an adapted RNA mixture.